Rating: Cautiously Bullish | Target Price: RMB 26.9-29.0 (fair value range, base case) | Current Price: RMB 24.87 (close, 2026-10-27) | Margin of Safety: +8.2% | Time Horizon: 6-12 months | Probability-weighted Expected Value: ~RMB 26.6 (+7.1%), plus a forward dividend yield of ~3.8%
China Resources Sanjiu is the absolute leader in branded TCM OTC (999 Ganmaoling has ranked No. 1 in the cold & cough category for 12 consecutive years), with ROE of ~16%, payout ratio above 50% for three consecutive years, and net cash of ~RMB 3.5 billion; its earnings quality and shareholder returns rank among the top in the TCM sector. In the first three quarters of 2026, revenue fell 2.6% and net profit attributable to shareholders fell 8.3%, mainly due to declining flu incidence pressuring the respiratory category and the pains of Kangtai (Kunming Pharmaceutical) channel reform; however, channel destocking (contract liabilities down 47.4% from the start of the year) and low-speed retail terminal growth constitute structural headwinds, and the slope of recovery is uncertain. The current price corresponds to a TTM P/E of 12.83x, at a single-digit percentile over the past 5 years; reverse calculation implies only ~1-1.6% perpetual growth — the market has already priced the company as a "zero-growth cash cow," and recovery drivers and options such as Kunming Pharmaceutical's loss reduction, normalization of the flu base, and the GLP-1 weight-loss drug BGM0504 are essentially not being paid for. However, the minority-interest structure of only 28% ownership in TSL (Tasly) and Kunming Pharmaceutical each, goodwill of RMB 7.063 billion (31.2% of net assets attributable to parent), and expanded centralized procurement constitute structural constraints on valuation recovery. Base-case fair value is RMB 26.9-29.0 (+8.2% to +16.6% vs. current price); combined with a ~3.8% forward dividend yield, odds are positive but not deeply undervalued. We are cautiously bullish, with the 2026Q4 flu season, Kunming Pharmaceutical's adjusted-core turnaround, and annual-report impairment testing as key verification windows.
What will change. Over the next 6-12 months, there are three verifiable change catalysts in fundamentals. First, normalization of the flu base — Q4 2025 through Q2 2026 is a low-to-medium base window for the respiratory category; from Q4 2026, the toughest YoY comparison period gradually passes, but the high base of Q4 2025 (quarterly revenue of RMB 9.616 billion and net profit attributable of RMB 1.068 billion) means 2026Q4 YoY will still be hard to turn positive; the intensity of the flu season will determine the degree of narrowing in declines. Second, Kunming Pharmaceutical's loss reduction — a net loss of RMB 366 million in the first three quarters of 2026 (of which RMB 203 million in impairments has already been fully recognized), with Q3 attributable loss narrowing to RMB 1.98 million (note: adjusted-core loss still ~RMB 46.16 million; turnaround quality remains to be verified); after Xuesaitong Soft Capsules entered the new National Essential Drug List, grassroots expansion is the main line for 2027 loss reduction. Third, BGM0504 (a GLP-1/GIP dual-target weight-loss drug, partnered with BrightGene Pharma) — its weight-loss indication NDA was accepted in June 2026; China Resources Sanjiu holds exclusive commercialization rights in mainland China, an option in valuation narrative rather than a current-profit event.
Primary stock price driver. Flu/respiratory disease incidence → respiratory category revenue is the largest revenue and earnings elasticity variable (2025Q4 accounted for ~30% of annual revenue), directly determining the FY2026 landing point and the magnitude of downward revisions to sell-side consensus; next is the two-way impact of Kunming Pharmaceutical's loss-reduction pace on minority interest drag and goodwill impairment expectations.
Expectation gap. This report diverges from the market in both directions. On earnings: sell-side consensus has FY2026 net profit attributable at ~RMB 3.43-3.74 billion, implying strong 2026Q4 YoY recovery of +19% to +49%; based on the actual trend of -8.3% in the first three quarters and management's language of "flu returning to normal levels," this report's own estimate for FY2026 net profit attributable is ~RMB 3.15 billion (implying ~RMB 0.99 billion in Q4, YoY ~-7%); consensus faces a downward revision risk of ~8-16% around the annual report, and the channel destocking indicated by contract liabilities at -47.4% has not yet been fully priced in by the Street. On valuation: the current price implies perpetual growth of only ~1-1.6%, with multiples at historical low percentiles providing a floor. Offsetting the two, odds are positive: bear case -30% to -23%, base case +8% to +17%, bull case +31% to +44%; probability-weighted expected value ~RMB 26.6 (+7.1%). The opportunity is verification-driven — "first falsify the downgrades, then deliver the re-rating" — rather than immediate trend-driven.
Verification catalysts and falsification conditions. Verification path: China CDC weekly flu surveillance (influenza-like illness percentage in southern provinces is already at medium-epidemic level and rising with fluctuations), Kunming Pharmaceutical's 2026Q4 adjusted-core turnaround, the 2026 annual report (expected March 2027) delivering a payout ratio above 50% and the goodwill impairment test conclusions, and BGM0504 review progress. Falsification path: annual goodwill impairment exceeding RMB 500 million; Kunming Pharmaceutical still posting quarterly losses in 2027H1; contract liabilities declining for two consecutive quarters with 2027H1 revenue not stabilizing; TCM centralized procurement expanding to Ganmaoling and other large OTC products with linked retail price comparisons; annual payout ratio falling below 45%.
Key evidence:
For 2023-2025, OCF/net profit attributable was 1.47/1.31/1.61 and FCF/net profit 1.07-1.24; weighted ROE was 16.07% (2025); cumulative dividends since listing totaled RMB 10.069 billion, about 6x cumulative fundraising, with no record of share-issuance dilution — the conversion of book profits to cash and shareholder-return discipline are among the best among similarly sized pharma companies. Two constraints must be noted simultaneously: first-three-quarter 2026 OCF fell 21.5% YoY, and weakening collections reduced this advantage to ~1.06x; net cash of ~RMB 3.5 billion is a consolidated figure, while minority interests of RMB 16.140 billion already account for ~41.6% of total equity — cash on Tasly's and Kunming Pharmaceutical's books (each 72% attributable to minorities) must be discounted in its meaning as a floor for A-share holders. The denominator of the TTM dividend yield of 4.04% is the already-paid FY2025 dividend; based on this report's FY2026 self-estimate and a 50% payout ratio, the forward dividend yield is ~3.8%.
Key evidence:
First three quarters: revenue RMB 21.410 billion (-2.62%), net profit attributable RMB 2.158 billion (-8.30%), adjusted core RMB 2.066 billion (-5.48%); Q3 adjusted core only -3.9%, with declines narrowing quarter by quarter; Tasly's first-three-quarter net profit attributable of RMB 1.103 billion (+12.0%) and adjusted core +34.96% offset the Kunming Pharmaceutical drag; gross margin improved 2.5pp against the trend (partly benefiting from the consolidation structural effect of Tasly and a ~-14% cost decline in Chinese medicinal materials over the past year). 999 Ganmaoling has ranked No. 1 in the cold & cough category for 12 consecutive years, and the company remains the No. 1 OTC manufacturer — brand share shows no loosening. But the attribution must be complete: sharply increased provisions for inventory write-downs (RMB 158 million) and receivables bad debts (~RMB 154 million), contract liabilities nearly halved, and operating cash flow at -21.5% together point to weakening channel sell-through and collections; management explicitly stated on the earnings call that retail pharmacies "face a wave of closures" and are "entering a mega-trend of low growth and stock competition" — channel destocking and low-speed terminal growth are structural components of the decline and cannot all be attributed to reversible flu disruption. Whether contract liabilities rebound QoQ in 2026Q4-2027Q1 is the direct signal for judging whether this thesis holds.
Key evidence:
Deducting net cash of ~RMB 3.5 billion from the current market cap of RMB 41.389 billion gives an operating value of ~RMB 37.9 billion; solving back with an equity cost of 9.5-10%, the implied perpetual growth is only ~1.2-1.6% — broadly consistent with the current near-zero organic growth (the 2023-2025 reported CAGR of 9.5% was mainly contributed by consolidation of Kunming Pharmaceutical and Tasly; organic growth was only +1.58% in 2025 and -8.3% in the first three quarters of 2026), meaning recoveries such as Kunming Pharmaceutical's loss reduction, normalization of the flu base, and BGM0504 approval are essentially not being paid for by the market. The zero-growth earnings power value (EPV) is ~RMB 18.8/share (2024-2025 adjusted-core net profit attributable average of RMB 3.126 billion = RMB 1.88/share, capitalized at a 10% equity cost, on an equity basis without double-counting net cash; adding back RMB 3.5 billion of net cash directly gives ~RMB 20.9/share), covering ~76% of the current price, with the remaining ~24% being the growth-option premium the market is paying. Downside protection must be assessed honestly: a forward dividend yield of ~3.8% and book value per share of RMB 13.60 (~RMB 9.4 after deducting goodwill, corresponding to a P/B of ~2.66x) provide partial support, but if the Kunming-system goodwill is cleared in the annual impairment test, the bear-case range (RMB 17.4-19.2) can pierce the zero-growth floor — the low percentile reflects both "cheap" and "cheap for a reason."
Key evidence:
The company holds only 28.00% of Tasly and 28.05% of Kunming Pharmaceutical; ~72% of profits from the two platforms accrue to minorities — of Tasly's RMB 1.103 billion net profit attributable in the first three quarters of 2026, ~RMB 790 million flowed to minority holders; the transmission of group-level recovery dividends (including Kunming's turnaround) to listed-company shareholders is discounted by 30% — a structural discount between "scaling up through M&A" and "shareholders making money," which also explains the reasonable component of the low-percentile valuation. In terms of goodwill composition, the Kunming system totals ~RMB 2.541 billion (consolidated through the 28.05%-owned Kunming Pharmaceutical); the revenue-growth assumptions in the 2025 annual impairment test have diverged sharply from Kunming's actual operations for two consecutive years, and the 2026 annual report (impairment test results disclosed March-April 2027) carries a real recognition risk — this report quantifies: a 50% impairment of Kunming-system goodwill would impact attributable profit by ~RMB 360 million, full impairment ~RMB 710 million (corresponding to ~-0.21 to -0.43 RMB in EPS). Buffering factors: Kunming's Q3 loss has already narrowed to roughly breakeven, the CR system has profit-smoothing incentives, and ~70% of Kunming-level goodwill is absorbed by minorities.
Key evidence:
The four verification points differ in nature and certainty: flu-season intensity (to be resolved December 2026 - January 2027) determines the degree of narrowing in Q4 respiratory declines — note that a single-week ILI percentage rising above 5% does not necessarily translate into positive revenue growth (southern regions reached 5.8% in summer 2026 while Q3 revenue still fell 10.87%), and under the high 2025Q4 base, YoY positivity was never the base case; whether Kunming Pharmaceutical achieves an adjusted-core turnaround in 2026Q4 (Q3 attributable loss reduction included ~RMB 44.18 million of non-recurring gains; still a loss on an adjusted basis) is a hard test of the channel reform's substance; if BGM0504 is approved in 2027, the company would become a scarce domestic GLP-1 dual-target commercialization story, but the R&D principal is BrightGene with Sanjiu participating via sales sharing — current profit contribution near zero, and any re-rating is narrative-level; an annual payout ratio above 50% is management's verbal guidance, not an institutional commitment (interim actual: 41.34%). Among the four, dividend delivery is the most certain, flu and Kunming next, and BGM0504 is purely an option.
| Metric | 2023FY | 2024FY | 2025FY | 2026Q1-Q3 | 2026Q3 Standalone |
|---|---|---|---|---|---|
| Revenue (RMB bn) | 24.739 | 27.617 | 31.603 | 21.410 | 6.396 |
| Revenue YoY | +36.83% | +11.63% | +14.43% | -2.62% | -10.87% |
| Net profit attributable (RMB bn) | 2.853 | 3.368 | 3.421 | 2.158 | 0.487 |
| Attributable YoY | +16.50% | +18.05% | +1.58% | -8.30% | -9.43% |
| Adjusted-core net profit attributable (RMB bn) | 2.711 | 3.118 | 3.134 | 2.066 | 0.470 |
| Adjusted-core YoY | +22.18% | +15.01% | +0.52% | -5.48% | -3.90% |
| Gross margin | 53.24% | 51.86% | 54.03% | 56.0% | — |
| Net margin attributable | 11.53% | 12.20% | 10.83% | 10.08% | 7.61% |
| Operating cash flow (RMB bn) | 4.192 | 4.402 | 5.513 | 2.297 | — |
| Free cash flow (RMB bn, OCF - capex) | 3.334 | 3.612 | 4.242 | 1.444 | — |
| Cash + cash-like assets (RMB bn, period end) | — | — | 10.530 | 7.494 | — |
| Interest-bearing debt (RMB bn, period end) | — | — | 6.451 | 3.993 | — |
| Debt-to-asset ratio | — | — | 34.58% | 30.07% | — |
| Contract liabilities (RMB bn, period end) | — | — | 1.783 | 0.937 | — |
Note: Cash-like assets include cash, trading financial assets, and large-denomination certificates of deposit (RMB 7.494 billion at end-2026Q3; consistent basis across both periods); capex for 2026Q1-Q3 was RMB 853 million; on October 16, 2026, the interim dividend of RMB 4.15 per 10 shares was implemented, totaling RMB 691 million (payout ratio 41.34%).
Reasons for metric changes (items with YoY ≥±20%): 2023 revenue +36.83% was mainly due to the consolidation of Kunming Pharmaceutical from January 2023 plus strong respiratory-category demand in a high-flu year; 2025 revenue +14.43% was mainly due to Tasly's consolidation on March 27, 2025 (cash consideration RMB 5.99 billion), while the legacy CHC business was dragged down by falling respiratory disease incidence (legacy basis: -6.75%); 2025 R&D spending +81.90% (RMB 1.734 billion) reflected the expanded R&D system after the Tasly acquisition; 2025 finance expenses swung from -RMB 24 million to +RMB 35 million, which the company attributed to increased interest expense on acquisition loans, falling back in 2026 with repayments; first-three-quarter 2026 asset impairment losses of RMB 289 million (+274%) and credit impairment losses of RMB 139 million (+197%) were attributed by the company to inventory write-downs, development expenditure impairment (termination of the QBH-196 and TSL-1502 clinical trials), and increased receivables bad-debt provisions; contract liabilities fell 47.44% from the start of the year, with the company only stating "lower advance receipts YoY" without explaining the underlying cause.
Revenue for the first three quarters was RMB 21.410 billion, -2.62% YoY — the first cumulative negative growth since Kunming Pharma was consolidated in 2023; net profit attributable to shareholders was RMB 2.158 billion, -8.30% YoY, with non-GAAP (deducting non-recurring items) at RMB 2.066 billion, -5.48%; Q3 standalone revenue was RMB 6.396 billion, -10.87% YoY, the largest single-quarter decline of the year, with attributable net profit of RMB 487 million (-9.43%) and non-GAAP of RMB 470 million (-3.90%) — the profit decline was notably smaller than the revenue decline. Three factors compounded: flu incidence falling back to normal levels, triggering a revenue correction in the respiratory category (per management commentary); Kunming Pharma's channel reform and tightening industry policy (Kunming Pharma's revenue for the first three quarters fell 42.7%, with a net loss of RMB 366 million, of which RMB 203 million in impairments was cleared out in a concentrated write-down); and the company's own impairment provisions reducing net profit by RMB 403 million (18.7% of attributable net profit for the first three quarters). The positives are equally clear: gross margin of 56.0%, +2.5 percentage points YoY (consolidation structure effect from Tashinly plus declining TCM raw material costs), and selling expense ratio of 27.6%, -0.3 percentage points YoY; Tashinly's attributable net profit for the first three quarters was RMB 1.103 billion (+12.0%), with non-GAAP +34.96% — consolidation synergies are being well realized on the profit side. Operating cash flow was RMB 2.297 billion, -21.47% YoY, corroborated by contract liabilities at -47.44%, indicating weak channel payment willingness. After disclosure, the stock closed at RMB 24.87 on October 27, essentially flat versus pre-disclosure — the market has largely priced in the earnings decline and impairments. Against sell-side consensus (post-Q3 reports, the latest research reports project FY2026 attributable net profit of RMB 3.431-3.442 billion, implying Q4 standalone growth of +19% or above), this report believes the Q4 recovery still carries downward revision risk — extrapolating the first-three-quarter trend, this report's own estimate is Q4 attributable net profit of approximately RMB 990 million, roughly -7% YoY.
Business model in brief. The company operates a hybrid model of "branded OTC + prescription TCM + formula granules + pharmaceutical distribution": CHC self-care centers on household staple brands such as 999 Ganmaoling, Piyanping, and Sanjiu Weitai, sold through retail pharmacies and e-commerce, with consumer self-selection and repeat-purchase revenue, carrying brand premium and some pricing power (999 Ganmaoling has been the category No. 1 for 12 consecutive years); prescription drugs (including Tashinly's Compound Danshen Dripping Pills and Kunming Pharma's Xuesaitong series) are driven by in-hospital academic promotion and essential drug list access; wholesale and retail is a low-margin, high-volume distribution business. The model is strongly asset-light — capex/depreciation & amortization is only about 0.88-0.89, with expansion driven mainly by M&A rather than organic construction.
Cash conversion of earnings. From 2023 to 2025, OCF/attributable net profit was 1.47/1.31/1.61, and FCF/net profit was 1.17/1.07/1.24 — book profit converts almost fully into freely disposable cash, a classic branded-consumer cash cow. In the first three quarters of 2026, OCF/attributable net profit fell to about 1.06 (OCF -21.5%), a borderline level that needs to be confirmed as stabilized in the 2026 annual report. On recurring earnings, the gap between non-GAAP and attributable profit is small (in 2025 the difference was about RMB 287 million, 8.4% of attributable profit; non-recurring items are mainly government subsidies and fair-value changes in financial assets, with an upward trend worth monitoring), and attributable profit has not been materially dressed up by one-off items; however, the R&D capitalization rate rose from 11.20% to 27.07% (in 2025, attributed by the company to M&A and increased internal R&D), and in 2026 the company terminated two clinical programs and took a RMB 139 million impairment on development expenditure — the quality of capitalized profit warrants tracking.
Return on capital. This report estimates 2025 ROIC at roughly 9.5% (NOPAT RMB 4.267 billion / invested capital of about RMB 44.9 billion), below the ~10% cost of equity — mainly because the large cash balance and RMB 7.063 billion of goodwill from the Tashinly acquisition dilute the denominator, a cost of "M&A-driven asset heavy-ification"; over the long run, if Kunming Pharma reduces losses and Tashinly synergies materialize, ROIC should recover, but current capital returns have not yet exceeded the cost of capital — a true reflection of the transition from "acquiring to get bigger" to "acquiring to get better."
Capex quality. Capex/depreciation is below 1 (0.88-0.89 in 2024-2025), indicating modest maintenance spending; planned 2026 capex is RMB 2.8 billion (mainly for capacity and digitalization), with incremental returns to be observed. No breakdown between maintenance and growth capex has been disclosed.
Moat and quality red flags. Moat: the nationwide 999 brand matrix + channel control via the "Sanjiu Trade Path" covering over 600,000 pharmacies + scale/cost advantages from 45 products exceeding RMB 100 million in sales each + central-SOE M&A integration capability. Red flags: (1) minority interest structure dilutes attributable profit (see Section III, Point C4); (2) earnings are highly dependent on the flu cycle of the cold/respiratory category (consecutive declines after the high 2023 base); (3) the wholesale-retail segment contributes 12.3% of revenue but only about 3% of gross profit, dragging down overall earnings quality; (4) goodwill/attributable net assets at 31.2% exceeds the one-third warning threshold.
Consistency of words and deeds: pragmatic, with occasional over-optimism in quantitative guidance. Three sets of promise-versus-delivery comparisons: (1) the "14th Five-Year Plan" goal of doubling revenue — from RMB 15.544 billion in 2021 to RMB 31.603 billion in 2025, +103.3%, delivered (though this includes the consolidation contributions of the Kunming Pharma and Tashinly acquisitions; organic contribution should be discounted); (2) both acquisitions — Kunming Pharma (transferred December 2022) and Tashinly (transferred March 2025, for RMB 5.990 billion) — closed on the pre-agreed timeline, demonstrating strong M&A execution; (3) the 2025 annual report planned for 2026 "revenue growth above industry average, profit growth matching revenue growth" — first-three-quarter revenue of -2.62% already lags the industry (about -1.3%), so this guidance is highly unlikely to be met, and full-year guidance credibility must be discounted. Earnings-call disclosure is candid: the company proactively disclosed Kunming Pharma's losses, the respiratory category's decline, and impairment details, without avoiding issues.
Shareholder friendliness: shareholder-friendly. Payout ratios for 2023-2025 were 51.96%/50.34%/50.59% respectively, and 41.34% for the 2026 interim (RMB 4.15 per 10 shares paid on October 16); management has explicitly stated it will maintain above 50% for the full year and gradually increase it. Cumulative dividends since listing total RMB 10.069 billion, roughly 6 times cumulative fundraising of RMB 1.666 billion; no dilutive share issuance or rights offerings, no market buybacks (only restricted-share repurchase cancellations). At the current price and this report's own 2026 earnings estimate, the forward dividend yield is about 3.8%.
Risk signals. Related-party transactions are a low share (in 2025, related-party sales accounted for only 1.79% of the top five customers); controlling shareholder China Resources Pharmaceutical Holdings holds 63.22%, fully circulating, with a pledge ratio of only 0.03% and no increase/decrease in holdings or insider trading records over the past year — a clean register. On personnel, director and Vice President Zhou Hui resigned in July 2026 due to retirement and stepped down as Chairman of Tashinly, with China Resources taking full control of Tashinly integration — a normal handover, but personnel continuity during the deep-water phase of integration warrants attention.
| Segment | 2025 Revenue Share | Gross Margin | 2025 YoY | Business Logic in One Sentence |
|---|---|---|---|---|
| CHC Self-Care | 47.82% | 61.67% | -14.67% (restated basis; legacy standalone basis -6.75%) | Branded OTC repeat-purchase business; 999 Ganmaoling No. 1 in category for 12 years |
| Prescription Drugs (including consolidated Tashinly & Kunming Pharma) | 38.27% | 58.81% | +101.38% (consolidation effect; legacy standalone basis +7.87%) | In-hospital academic promotion + essential drug list access; Compound Danshen Dripping Pills / Xuesaitong |
| Drug & Device Wholesale-Retail | 12.33% | 14.29% | +15.56% | Commercial distribution volume business, dragging down overall gross margin |
Measuring gross profit contribution by "revenue share × gross margin": CHC is about 55%, prescription drugs about 42%, and wholesale-retail about 3% — the profit engine is CHC self-care, which is also a 100%-owned asset. Prescription drug gross profit is now close to CHC in scale, but roughly 72% of the Tashinly and Kunming Pharma portion belongs to minority shareholders, making CHC even more dominant as the attributable profit engine. The structure shifted sharply in H1 2026: CHC revenue was RMB 6.130 billion (-23.29%) and prescription drugs RMB 6.876 billion (+42.14%, including Kunming Pharma consolidation adjustments) — prescription drug revenue exceeded CHC for the first time. Within this, Tashinly (innovative TCM, gross margin 70.64%) is the group's highest-margin asset, while Kunming Pharma (traditional Chinese medicine, 63.78%), hit by centralized procurement and channel transformation, saw 2025 revenue fall 33.68% and posted a net loss of RMB 370 million in H1 2026. The gross margin structure gap between the highest and lowest is about 47 percentage points (CHC 61.67% vs. wholesale-retail 14.29%) — essentially two different businesses: branded manufacturing vs. distribution. Prescription drugs and CHC have similar gross margins but vastly different profit ownership structures — this is the key to understanding why the company's "consolidated statements look good but attributable elasticity is discounted."
Accounting red flags (by severity):
Cross-period consistency:
Current market data and percentile. Stock price RMB 24.87 (close, 2026-10-27), total shares 1.6642 billion, total market cap RMB 41.389 billion; TTM P/E of 12.83x, at roughly the 6-9% percentile of the past 5 years (calculated by this report using exchange valuation series; figures vary slightly across series); P/B of 1.83x (roughly the 12% percentile over 5 years); TTM dividend yield 4.04%. On a forward basis, sell-side consensus FY2026 EPS of RMB 2.25 implies about 11.1x, and FY2027 of about RMB 2.48 implies about 10.0x; using this report's own FY2026 attributable net profit estimate of RMB 3.15 billion, the multiple is about 13.1x. Peer comparison (table below): the company's P/E trades at roughly a 30% discount to the median of 6 peers (about 18.26x), while its ROE is above the peer median — earnings do not exhibit deep-trough characteristics (TTM non-GAAP profit is only about 3% below 2024). The low percentile can serve as a cheapness/expensiveness signal, but the 2021-2022 TCM rally and post-consolidation EPS restructuring make historical percentiles reference-only.
| Company | PE (TTM) | PB | 2025 Revenue Growth | ROE | Note |
|---|---|---|---|---|---|
| China Resources Sanjiu | 12.83 | 1.83 | +14.43% (consolidated) | 16.07% (weighted) | OTC leader, net cash RMB 3.5 billion |
| Yunnan Baiyao | 18.26 | 2.33 | +2.88% | 13.07% | Commercial business over half of revenue, dragging gross margin |
| Lingrui Pharmaceutical | 14.76 | 3.56 | +10.07% | 23.47% | Patch niche; scale only 1/8 of Sanjiu's |
| Jichuan Pharmaceutical | 13.22 | 1.76 | -22.43% | 12.13% | Dual-product shrinkage under centralized procurement |
| Yiling Pharmaceutical | 18.89 | 2.38 | +20.24% | 12.13% | Respiratory peer, high volatility |
| Taiji Group | Loss-making | 1.93 | -15.23% | 0.73% (first three quarters 2026) | Profit collapse from channel destocking |
| Pien Tze Huang | 42.74 | 5.29 | — | 14.98% | Single-product slowdown; not comparable |
Market-implied expectations. Back-solving from operating value of about RMB 37.9 billion (market cap minus net cash), at a 9.5-10% cost of equity the current price implies perpetual growth of only about 1.2-1.6% — in one sentence: "the current price requires the company to be essentially zero-growth in the future, while the reality is that Tashinly consolidation synergies are already being realized (non-GAAP +35%), Kunming Pharma's loss-reduction path is visible, and the pipeline includes the accepted GLP-1 weight-loss NDA." The premium paid for the growth option is only about 24%; the pricing reflects reasonable concerns about the flu trough becoming the norm, centralized procurement expansion, and goodwill — not an uncaused discount. This implied expectation broadly matches the near-zero organic growth status quo — the true expectation gap lies not in "the market wrongly killing growth" but in "the market has not yet paid for Kunming Pharma's loss reduction and flu normalization."
Three-tier value (EPV). Zero-growth EPV is about RMB 18.8 per share (2024-2025 average non-GAAP attributable profit of RMB 3.126 billion ≈ RMB 1.88 per share, capitalized at a 10% cost of equity, on an equity basis without double-counting net cash back; sensitivity range RMB 17.1-20.9 at discount rates of 11%-9%), with asset value (book value per share RMB 13.60, about RMB 9.4 after deducting goodwill) as an independent floor reference. About 76% of the current price is supported by zero-growth value, and about 24% is a growth option (Kunming Pharma loss reduction, flu normalization recovery, BGM0504 and 55 pipeline programs) — structurally not a deep discount "paying only for zero growth," but option pricing is clearly conservative.
Three scenarios and odds.
| Scenario | Probability | Fair Value Range | vs. Current Price | Key Swing Factor |
|---|---|---|---|---|
| Bear | 30% | RMB 17.4-19.2 | -30%~-23% | Flu remains weak through 2027 + centralized procurement/price-comparison expansion + RMB 500-800 million goodwill impairment in the Kunming Pharma system: normalized earnings fall to about RMB 2.9 billion × 10-11x, cross-validated by P/B of 1.35x |
| Base | 45% | RMB 26.9-29.0 | +8%~+17% | FY2026 attributable profit RMB 3.15 billion, FY2027 recovering to RMB 3.45 billion (+9.5%: normalized flu base + full-year Kunming Pharma loss reduction + second year of Tashinly synergies) × 13-14x (anchored to FY2027 EPS of about RMB 2.07; this multiple is a 0.71-0.77x discount to the peer median of 18.26x and a 0.75-0.81x discount to the company's own 5-year median of about 17.3x — independently anchored; the discount reflects a lower growth center and the goodwill/minority interest structure) |
| Bull | 25% | RMB 32.7-35.9 | +31%~+44% | Heavy flu season + full-year Kunming Pharma turnaround + BGM0504 approval: FY2027 attributable profit RMB 3.75-3.85 billion × 14.5-15.5x (referencing Lingrui at 14.76x / Yunnan Baiyao at 18.26x current levels and the lower end of the company's own 5-year median) |
The probability-weighted expectation is about RMB 26.6, +7.1% vs. the current price, plus a forward dividend of about 3.8% — odds slightly positive, distribution tilted modestly upward; the current price sits between the bear and base cases, close to the lower edge of the base case — an asymmetric structure of "downside partially cushioned by dividends and zero-growth value, upside contingent on verified recovery." However, the bear case with 30% probability (-23% or more) cannot be ignored.
In-house earnings forecast (reconciliation anchor). FY2026: revenue RMB 30.26-30.74 billion (about -3.5%), attributable profit RMB 3.01-3.29 billion (point estimate RMB 3.15 billion, about -7.9%) — assuming Q4 standalone attributable profit of RMB 990 million, about -7% YoY, consistent with management's "flu back to normal levels" commentary and the first-three-quarter non-GAAP trend. FY2027: revenue RMB 31.41-32.18 billion (+3.0%~+5.5%), attributable profit RMB 3.35-3.55 billion (point estimate RMB 3.45 billion, +9.5%). Versus the sell side: this report is about 8-16% below consensus (RMB 3.43-3.74 billion), with the entire divergence in the strength of the Q4 recovery; if the flu season proves strong, there is room to revise these figures upward — this is the core point of divergence from the street.
Conclusion. Reasonably cheap: the mismatch between quality (leadership share, cash conversion, dividend discipline) and price (single-digit percentile, implied zero growth) points toward undervaluation, but the minority interest structure, the real risk of goodwill impairment, and centralized procurement expansion keep it short of "significantly undervalued." Target price RMB 26.9-29.0 (base-case fair value), margin of safety +8.2% (base-case lower bound) — insufficient to support an aggressive full position, but combined with a forward dividend yield of about 3.8%, it forms the basis of a cautious bullish stance of "first absorbing the downward revisions, then realizing the recovery."
Industry size. The company's core segments are Chinese patent medicine OTC, TCM formula granules, and TCM prescription drugs. ① OTC market: According to the China Non-prescription Medicines Association's "2025 China OTC Market Report" (data source: IQVIA), the 2025 market size was approximately RMB 300 billion, essentially flat for the year; cough/cold & respiratory, digestive/gut, and vitamins & minerals—the three major categories—account for roughly 45% combined (about RMB 135 billion). ② Above-scale TCM patent medicine industry: Under National Bureau of Statistics methodology, 2021 revenue was RMB 486.2 billion, with a 2020–2025 revenue CAGR of about 2.61% (cited in China Kangfei's 2025 annual report)—a mature, low-growth industry. ③ TCM formula granules: The 2021 market was RMB 25.245 billion (China Health Industry Information Center); after the national standards switch and centralized procurement, the segment entered a price-for-volume restructuring period, with widely divergent size forecasts (a 2025 forecast of about RMB 53.2 billion circulating on aggregator sites is third-hand data, unverified). ④ Reference frame: Menet's data put the total China pharmaceutical market at RMB 1,260.1 billion for the first three quarters of 2025, -1.0% YoY. The industry logic for the next 3–5 years is mild volume-price growth in the low single digits of 2–4%: aging-driven expansion of chronic disease demand (population aged 60+ at 22.0%), prescription outflow (out-of-hospital uptake exceeding RMB 200 billion in 2025), and online channel expansion are positive contributors; procurement-driven price cuts and pharmacy terminal consolidation are negative. 2025 was a trough year: cold/respiratory OTC fell -7.8% YoY (weak flu season), and revenue of above-scale pharmaceutical manufacturers fell -1.2%.
Value chain and value distribution. Upstream: TCM raw material prices fell back into a downtrend from July 2024 after continuous rises in 2020–2023; Eastmoney's TCM raw materials base-fixed index was -14.1% over the past year—clearly positive for TCM patent medicine gross margins on the cost side (evidenced by this company's +2.5pp gross margin in the first three quarters of 2026 and Yabao's +4.2pp); manufacturers' bargaining power over the fragmented farming end is moderately strong, with leaders smoothing volatility via GAP bases and strategic stockpiles. Midstream manufacturing is where value is retained: the company's pharmaceutical industrial gross margin was 60.40%, CHC segment 61.67%, well above downstream wholesale/retail (14.29%); branded OTC has low price elasticity of demand and carries brand premiums, but procurement-covered products and price-comparison policies are compressing pricing freedom in this segment. Downstream terminals are undergoing dramatic change: at end-2025 there were about 656,500 retail pharmacies, with a net closure of about 27,200 stores (NMPA); chain concentration was 62.3%, with the top-10 chains accounting for nearly 58% of sales with about 20% of stores; hospital terminals were -2.5% in 2025; online B2C (RMB 73.2 billion, +29.1%) and O2O (RMB 29.1 billion, +29.6%) were the only high-growth channels. The company sits in the midstream branded manufacturing segment with strong bargaining power over downstream: its "999 Commercial Pathway" covering over 600,000 pharmacies is a benchmark channel system in the industry, with strategic partnerships with JD Pharmacy and Alibaba Health—among the deepest channel positioning among peers; the pharmacy closure wave hits price-sensitive smaller brands harder, while top brands actually gain terminal concessions due to their traffic-drawing role.
Supply-demand and competitive landscape. Demand is driven by aging, flu cycles, prescription outflow, and online migration; on the supply side, the stock of OTC approvals is enormous and competition is homogenized (225 newly registered OTC products in 2025, +27%), and formula granule producers have expanded from 6 to several hundred—oversupply; the industry overall faces excess supply. Concentration: the company has ranked first in comprehensive OTC company rankings for consecutive years (OTC Association; ~21% comprehensive share cited by brokers in 2022); retail market share of ~28% in cold-category TCM patent medicines is the highest (Menet, 2021 basis); the Ganmaoling granule single product accounts for about 23% of cold TCM patent medicines in urban physical pharmacies (Menet, 2023), with annual sales of about RMB 3.75 billion (2024, ~25% of CHC revenue); in the broader respiratory category in physical pharmacies, the 2022-era ranking was Yiling 22.4% (during Lianhua Qingwen's volume surge) > China Resources Sanjiu 14.83% > Nin Jiom 13.38%. Entry barriers: brands (consumers buy by brand; new-brand customer acquisition costs are extremely high), channels (management of 600,000 pharmacies), approvals and classical formulas (the company has 7 approved classical formulas and 4 under application), and scale economics (45 products exceeding RMB 100 million in sales). Competition is mainly brand marketing and channel contest, not price-war-driven; within procurement-covered products, price competition is brutal (the third TCM patent medicine joint procurement averaged -68%).
Cycles and regulation. The industry is in the policy-driven clearing, downturn phase of its mature period: demand grows steadily at low single digits; 2025 was a cyclical low with a weak flu season, procurement impact, and pharmacy clearing all overlapping; 2026 offers a window for mild recovery from flu normalization and falling costs. Key policies: ① normalization of TCM patent medicine procurement—the national joint procurement has reached its fourth batch (bids opened May 2026, covering 89 drugs, average price cuts of 50–68%, first procurement year starting 2026-09-21, cycle through end-2028); ② formula granule procurement—the Shandong-led 15-province alliance shortlisted 59 companies as prospective winners, average price cut of 50.77%; ③ drug price-comparison governance—29 provinces have launched price-comparison mini-programs for designated pharmacies, and the 2026 State Council General Office "Several Opinions on Improving the Drug Price Formation Mechanism" promotes public price comparison; systematic pressure on OTC retail price transparency exists (in September 2024, Anhui's draft proposal to include OTC in procurement wiped out about RMB 10 billion of the company's market cap in 4 trading days—a precedent of tail risk); ④ industry support—the February 2026 "Implementation Plan for High-Quality Development of the TCM Industry (2026–2030)" by the MIIT and seven other departments. The overall regulatory direction is "neutral-to-negative on price, positive on leading-player concentration in structure": branded OTC is mainly patient self-paid with low price elasticity, less impacted than prescription drugs, and policy accelerates clearing of tail players, concentrating share toward leaders.
Company positioning within the industry. Absolute leader in branded TCM OTC, with stable and slowly rising share: first among OTC manufacturers, 999 Ganmaoling has been category No. 1 for 12 years; prescription drugs have risen to a platform-based layout (after consolidating Tasly and KPC, the company ranks top-three among listed companies in TCM industrial revenue, alongside Baiyunshan and Yunnan Baiyao in the first tier); in formula granules, it is a first-tier challenger (former leader China TCM shrank with -11% revenue in 2025H1; the company seeks share via cost control and its "original source, original taste" brand—specific share undisclosed). Sources of moat: brand matrix (999 + Tianhe, Shunfeng, Aonuo, KPC 1381), channel depth, and central-SOE M&A integration capability. Risk points: CHC segment -14.7% in 2025 (restated basis) and -23.3% in 2026H1, under short-term pressure; but its value-distribution position with industrial gross margins of 60%+ remains intact.
Generic financial frameworks easily miss three defining dimensions of TCM OTC; they are listed separately:
First, brand is a moat outside the balance sheet, and it is quantitatively trackable. The company's comprehensive OTC share is about 21%, and Ganmaoling's single-product retail share is 23%–28%; brand rankings (OTC Association annual list, Menet retail data) serve as an annual verification yardstick of share trends; the value of the 999 brand lies in creating repeat purchases and pricing power in "cold medicine," a low-barrier category—which explains the 47-percentage-point gap between CHC gross margin of 61.67% and wholesale/retail's 14.29%. Tracking indicators: whether cold/cough retail share holds No. 1, and category expansion from classical formulas and new approvals (Yiguanjian granules approved in 2026, Zaoren Ningxin dropping pills approved).
Second, channel inventory is a leading-lagging trap for OTC earnings. The retail pharmacy closure wave (net -27,200 stores in 2025) + outpatient pooled-account diversion + price-comparison transparency are shifting channels from "stock-loading growth" to "sell-through replenishment"; the three consecutive-period declines in contract liabilities from 1.861 to 1.783 to 0.937 billion RMB, along with OCF -21.5%, are direct signals of channel destocking—the "flu drag" and "destocking drag" on revenue are hard to separate in the financials, while the latter determines whether revenue can stabilize in 2027. Tracking indicators: quarter-over-quarter contract liabilities (whether 2026Q4–2027Q1 rebound), pharmacy cold-category sell-through (Zhongkang/Menet monthly), receivables and inventory turnover.
Third, policy sets the ceiling and floor of valuation. Procurement and price comparison are double-edged swords hanging over both the prescription side (fourth joint batch in execution) and the retail side (price-comparison mini-programs): the neutral case implies mid-single-digit annualized profit erosion; the tail case (large OTC single products included in procurement with linked retail prices) would directly undermine the "brand self-pricing" logic—this is a core component of the bear case and the main basis for the 30% bear-case probability. Offsetting policies (essential drug list, TCM industry high-quality development plan) benefit grassroots volume expansion of essential drug products such as KPC's Xuesaitong.
Overall assessment. Cautiously bullish, confidence 0.55, time horizon 6–12 months. This is a company of "high quality, low price, structural discount": the cash generation and dividend discipline of a branded OTC leader form the floor, while a 12.8x P/E at a single-digit historical percentile and implied perpetual growth of only 1–1.6% form the upside option; however, net profit attributable is discounted ~30% by the 28% shareholding structure, the annual impairment test on RMB 7.063 billion of goodwill is approaching, and consensus still has about 8–16% room for downward revision—determining that the repair path is "digest first, deliver later" rather than a V-shaped reversal. Base fair value RMB 26.9–29.0, margin of safety +8.2% (base-case lower-bound basis), coupled with a forward dividend yield of about 3.8%; the odds structure skews positive but position conviction needs to be driven by verification events.
Strategy implications. The current price sits in a transition zone "between bear and base cases": for long-term capital, dividend yield and zero-growth value provide a floor reference; phased entry before verification points materialize is preferable to a single build. For trading capital, the December 2026–January 2027 flu data and the March 2027 annual report (dividend proposal + goodwill impairment test + full-year KPC data) are the two most important time windows.
Key risk warnings. ① Goodwill impairment on the KPC system (RMB 2.541 billion, annual-report test window); ② a weak flu season leaving Q4 declines un-narrowed and triggering a second consensus downgrade (UBS already cut to Neutral on October 21, target price RMB 27); ③ expansion of TCM patent medicine procurement/price comparison to large OTC single products; ④ channel destocking persisting through 2027H1; ⑤ minority shareholder structure continuously discounting the transmission of group-level recovery to attributable profit.
Monitoring and verification arrangements. The following conditions are on the monitoring list: weekly flu surveillance reports (southern ILI percentage and positivity rate), KPC's 2026Q4 and annual report adjusted (ex-non-recurring) results, 2026 annual report payout ratio and goodwill impairment provision, quarter-over-quarter contract liabilities, BGM0504 review progress, and the fifth-batch TCM patent medicine procurement catalog; on price, a fall below RMB 17.4 (bear-case lower edge) triggers a re-examination of the valuation logic, a rise above RMB 26.9 (base-case lower edge) confirms recovery initiation, and touching RMB 29.0 (base-case upper edge) means the margin of safety is exhausted—re-evaluate. The next earnings reconciliation will be anchored to this report's FY2026 forecasts (revenue RMB 30.26–30.74 billion, net profit attributable RMB 3.01–3.29 billion), checked three ways against management guidance and sell-side consensus.
Notes and data sources: Financial data are taken from the company's 2023–2025 annual reports, 2026 semi-annual report and Q3 report (cninfo); impairment details from the October 24, 2026 "Announcement on Provisions for Various Asset Impairment Losses for the First Three Quarters of 2026"; management commentary from the October 24, 2026 Q3 earnings briefing investor relations activity record; industry data from the China Non-prescription Medicines Association's "2025 China OTC Market Report" (data source: IQVIA), the National Bureau of Statistics, Menet, the NMPA and the NHSA; peer and sell-side data as of 2026-10-27. Valuation percentiles are calculated in this report from exchange valuation series (6%–9% depending on series basis); the three scenarios and EPV are this report's own estimates. The forward-looking content of this report is derived from public information and assumptions and does not constitute investment advice.